The trial design allowed us to evaluate the efficacy of abiraterone/prednisone versus olaparib versus a combination of the two treatments as first-line treatment for men with mCRPC whose tumors had specific genetic alterations. The results clearly indicate that the combination of abiraterone/prednisone plus olaparib resulted in higher response rates and longer time to disease progression compared to either agent alone or sequentially.
Approximately 25 percent of patients with mCRPC express unique genetic alterations known as Homologous Recombination-Repair Mutations (HRRms), namely in the BRCA1/2 and ATM genes, underscoring the need for more targeted therapies for this subgroup of patients.
Olaparib, a PARP inhibitor that inhibits the poly ADP ribose polymerase enzyme, which is involved in DNA repair, was approved by the FDA in 2020 for the treatment of mCRPC for patients with HRRms who experienced cancer progression following prior hormonal therapy.
[
Collection
]
[
|
...
]